

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number  
WO 03/020253 A2

(51) International Patent Classification: A61K 31/00

DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LI, LU, MN, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM

(21) International Application Number: PCT/US02/27336

(22) International Filing Date: 27 August 2002 (27.08.2002)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BE, BJ, CL, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(26) Publication Language: English

(30) Priority Data:  
60/315,386 28 August 2001 (28.08.2001) US

## Declarations under Rule 4.17:

as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(a)) for the following designations: **AE, AG, AL, AM, AR, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LI, LU, MN, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, ZW**  
**Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)**  
**European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR)**  
**OAPI patent (BE, BJ, CL, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)**


as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(b)) for all designations

{continued on next page}

(54) Title: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ASTHMA



WO 03/020253 A2



(57) Abstract: Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and formoterol



**Published:**

*without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ASTHMA

The present invention is directed to aerosol suspension formulations which  
5 are free of chlorofluorocarbons (CFC's). More specifically, the present invention is  
directed to formulations that are substantially free of CFC's and formulations that  
have particular utility in medicinal applications, especially in metered dose  
pressurized inhalers (MDI's).

Metered dose inhalers have proven to be effective oral and nasal delivery  
10 systems that have been used extensively for delivering bronchodilating and  
steroidal compounds to asthmatics, as well as delivering other compounds such as  
pentamidine and non-bronchodilator anti-inflammatory drugs. The rapid onset of  
activity of compounds administered in this manner and the absence of any  
significant side effects have resulted in a large number of compounds being  
15 formulated for administration via this route. Typically, the drug is delivered to the  
patient by a propellant system generally comprising one or more propellants which  
have the appropriate vapor pressure and which are suitable for oral or nasal  
administration. The more preferred propellant systems typically comprise CFC  
20 propellant 11, CFC propellant 12, CFC propellant 114 or mixtures thereof. Often  
the vapor pressure of the propellant systems is adjusted by admixing a less volatile  
liquid excipient with the propellant.

However, propellants CFC 11, CFC 12 and CFC 114 belong to a class of  
compounds known as chlorofluorocarbons, which have been linked to the depletion

of ozone in the atmosphere. It has been postulated that ozone blocks certain harmful UV rays and thus a decrease in the atmospheric ozone content will result in an increase in the incidence of skin cancer. In the 1970's certain steps were taken to reduce the CFC emissions from aerosols. Other propellants, such as 5 hydrocarbons, were used, or the product was delivered in a different manner. Because CFC usage in medicinal applications is relatively low, i.e. less than 1% of total CFC emissions, and because of the health benefits associated with metered dose inhalers, steps were not taken at that time to restrict the use of CFC propellants in metered dose inhalers.

10        However, continuing and more sophisticated ozone measurements have indicated that the earlier restrictions in CFC usage were insufficient and that additional, significant steps should be taken to drastically reduce CFC emissions. Recommendations have been made that CFC production be virtually discontinued. As a result, it may not be possible to continue to use CFC propellants in the 15 intermediate and long term. While some efforts have been made to use non-pressurized metered dose inhalers, many of these devices have not been completely successful. Some of the performance issues related to these are: delivery of uniform doses, mechanical complexity, provision of the required doses per unit of an aerosol container, compliance with stringent regulatory standards, 20 and difficulty for individuals to utilize because they are bulky and/or cumbersome for patient use, particularly when patient has an acute need for the medication.

As a result, there is a need for CFC-free pressurized aerosol formulations, such as metered dose inhalers, which are substantially free of CFC's. Non-CFC propellant systems must meet several criteria for pressurized metered dose

inhalers. They must be non-toxic, stable and non-reactive with the medicament and the other major components in the valve/actuator. One propellant which has been found to be suitable is  $\text{CF}_3\text{CH}_2\text{AF}_3$ , also known as HFA 227, HFC 227 or 1,1,1,2,3,3,3 heptafluoropropane. From hereon forward, this propellant will be referred to as HFA 227. However, certain physical properties, i.e., polarity and solubility of HFA 227 differ from those of commonly used CFC propellants.

Commonly used surfactants may be insoluble in HFA 227. Moreover, where the medicament is to be delivered as a solution, the medicament may not be readily soluble in this propellant. The polarity difference between HFA 227 and the

previously used CFC propellants may result in a different delivery of the medicament when HFA 227 replaces a CFC propellant. The medicament may cream, settle or agglomerate in the non-CFC propellant even though this did not occur in the CFC propellant. Another such non-chlorofluorocarbon propellant is Hydrofluorocarbon 134a, also known as 1,1,1,2-tetrafluoroethane or HFA 134a.

From hereon forward, this propellant will be referred to as HFA 134a

Prior art formulations containing mometasone in combination with HFA 227 in a metered dose inhaler utilize ethanol to suspend the mometasone in a crystalline state in combination with the propellant. These formulations have improved stability over time.

The specific combinations noted above may not provide the desired solubility, stability, low toxicity, exact dosage, correct particle size (if suspension) and/or compatibility with commonly used valve assemblies of metered dose inhalers. Accordingly, there exists a need for CFC free formulations for the

treatment of asthma, and processes for producing the same, that do not suffer from the aforementioned infirmities.

### SUMMARY OF THE INVENTION

Accordingly, the present invention is directed to a process for producing non-toxic formulations that are substantially free of CFC's that have improved stability and compatibility with the medicament and which are relatively easily manufactured.

The present invention is also directed to a metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3,-heptafluoropropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400  $\mu$ g of mometasone furoate to about 12  $\mu$ g of formoterol fumarate to about 50  $\mu$ g of mometasone furoate to about 6  $\mu$ g of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, and wherein the formulation is substantially free of a carrier.

The present invention is also directed to a metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; about 0.05% to about 0.3% by weight of a bulking agent; and 1,1,1,2-tetrafluoroethane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400  $\mu$ g of mometasone furoate to about 12  $\mu$ g of formoterol fumarate to about 50  $\mu$ g of mometasone furoate to about 6  $\mu$ g of

formoterol fumarate, and wherein the formoterol fumarate flocculates with the mometasone furoate.

The present invention is also directed to a process for producing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3,-heptafluopropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400 µg of mometasone furoate to about 12 µg of formoterol fumarate to about 50 µg of mometasone furoate to about 6 µg of formoterol fumarate, and wherein the formoterol fumarate is flocculated with the mometasone furoate in said aerosol suspension formulation, and wherein the formulation is free of a bulking agent, comprising the steps of: mixing a dry powder blend of micronized mometasone furoate and formoterol fumarate with a dry powder surfactant to form a uniform mixture; filling said mixture into a metered dose inhaler canister; crimping said canister with a metering valve; and filling said canister with a nonchlorofluorocarbon propellant. The present invention is also directed to the products produced by the foregoing process.

The present invention is also directed to a metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; a dry powder surfactant ;and 1,1,1,2,3,3,3,-heptafluopropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400 µg of mometasone furoate to about 12 µg of formoterol fumarate to about 50 µg of mometasone furoate to about 6 µg of formoterol fumarate, wherein the formoterol fumarate flocculates with the

mometasone furoate, wherein the formulation is free of additional excipients, and wherein the metered dose inhaler emits a dose having uniform drug content upon actuation of the metered dose inhaler.

The present invention is also directed to a metered dose inhaler containing

5 an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3,-heptaflouopropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400 µg of mometasone furoate to about 12 µg of formoterol fumarate to about 50 µg of

10 mometasone furoate to about 6 µg of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, and wherein the formulation contains less than 0.1% of an epoxide degradation product of mometasone furoate.

The present invention is also directed to a metered dose inhaler containing

an aerosol suspension formulation for inhalation, said aerosol suspension

15 formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3,-heptaflouopropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400 µg of mometasone furoate to about 12 µg of formoterol fumarate to about 50 µg of

20 mometasone furoate to about 6 µg of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, wherein the percent of the fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85% and wherein said fine particles have a particle size of less than about 4.7 µm.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is the mometasone furoate Andersen Cascade Impactor profile of the mean of three units of the formoterol fumarate/mometasone furoate 6/50 µg actuation combination inhaler with HFA 227 and no bulking agent.

5 Figure 2 is the formoterol fumarate Andersen Cascade Impactor profile of the mean of three units of the formoterol fumarate/mometasone furoate 6/50 µg actuation combination inhaler with HFA 227 and no bulking agent.

10 Figure 3 is the formoterol fumarate Andersen Cascade Impactor profile of the mean of three units of the formoterol fumarate/mometasone furoate 6/50 µg actuation combination inhaler and HFA 134a with low bulking agent.

Figure 4 is the mometasone furoate Andersen Cascade Impactor profile of the mean of three units of the formoterol fumarate/mometasone furoate 6/50 µg actuation combination inhaler and HFA 134a with low bulking agent.

DETAILED DESCRIPTION OF THE INVENTION

15 Mometasone furoate, the active component of ELOCON® lotion, cream, and ointment, is an anti-inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11(beta),17-dihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione 17-(2-furoate). It is practically insoluble in water; slightly soluble in methanol, ethanol, and isopropanol; soluble in acetone and chloroform; and freely soluble in  
20 tetrahydrofuran. Its partition coefficient between octanol and water is greater than 5000. Mometasone can exist in various hydrated, crystalline and enantiomeric forms, e.g., as a monohydrate. This product is available from Schering-Plough Corporation, Kenilworth, New Jersey.

Formoterol fumarate is a selective beta<sub>2</sub>-adrenergic bronchodilator. Its chemical name is ( $\pm$ )-2-hydroxy-5-[(1RS)-1-hydroxy-2-[(1RS)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]formanilide fumarate dihydrate.

Formoterol fumarate is a white to yellowish crystalline powder, which is reportedly freely soluble in glacial acetic acid, soluble in methanol, sparingly soluble in ethanol and isopropanol, slightly soluble in water, and practically insoluble in acetone, ethyl acetate, and diethyl ether. Formoterol fumarate can exist in various hydrated, crystalline, and enantiomeric forms, e.g., as a monohydrate. This product is available commercially from Novartis Corporation, East Hanover, New Jersey.

10 The invention is of particular utility where the medicament is formoterol fumarate and mometasone furoate, or end salts, enantiomers and clathrates thereof.

15 The mometasone furoate and formoterol fumarate can be in a weight ratio of about 1 to 1 mometasone furoate to formoterol fumarate, or about 50 to 1 mometasone furoate to formoterol fumarate, or about 20 to 1 mometasone furoate to formoterol fumarate, or about 12 to 1 mometasone furoate to formoterol fumarate, or about 16 to 1 mometasone furoate to formoterol fumarate, or about 10 to 1 mometasone furoate to formoterol fumarate, or about 8 to 1 mometasone furoate to formoterol fumarate.

20 These ratios roughly equate to a dose range of 6  $\mu$ g of formoterol fumarate to 50  $\mu$ g of mometasone furoate per dose, or about 6  $\mu$ g to 100  $\mu$ g of formoterol fumarate to mometasone furoate per dose, or about 8  $\mu$ g to 100  $\mu$ g of formoterol fumarate to mometasone furoate per dose, or about 6  $\mu$ g to 200  $\mu$ g of formoterol fumarate to mometasone furoate per dose, or about 8  $\mu$ g to 200  $\mu$ g of formoterol

fumarate to mometasone furoate per dose, or about 12 µg to 200 µg of formoterol fumarate to mometasone furoate per dose, or about 12 µg to 400 µg of formoterol fumarate to mometasone furoate per dose.

Propellant-based pharmaceutical aerosol formulations in the art typically use 5 a mixture of liquid chlorofluorocarbons as the propellant, although many others use a single propellant. As is known in the art, the propellant serves as a vehicle for both the active ingredients and excipients. Fluorotrichloromethane, dichlorodifluoromethane and dichlorotetrafluoroethane are the most commonly used propellants in aerosol formulations for administration by inhalation. Such 10 chlorofluorocarbons (CFC's), however, have been implicated in the destruction of the ozone layer and their production is being phased out. HFA 134a and HFA 227 are said to be less harmful to the ozone than many chlorofluorocarbon propellants, and both either individually or in combination are considered to be used within the 15 scope of the present invention. However, conventional chlorofluorocarbons, or mixtures thereof, may also be used as propellants for the formulations of the present invention.

As is known to one of skill in the art, a carrier and/or bulking agent is an inert substance in which or on to which the active drug ingredient(s) and excipient(s) if present are dispersed. When the formulations of the present invention utilize HFA 20 227 as the propellant, it has been surprisingly found that a carrier is not necessary. Accordingly there is disclosed a metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3,-heptafluopropane; wherein the

ratio of mometasone furoate to formoterol fumarate is about 400 µg of mometasone furoate to about 12 µg of formoterol fumarate to about 50 µg of mometasone furoate to about 6 µg of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, and wherein the formulation is 5 substantially free of a carrier.

The processes for producing the formulations of the present invention preferably utilize HFA 227 or HFA 134a, or a combination thereof, in combination with mometasone furoate and formoterol fumarate, optionally, a liquid excipient, and optionally a surfactant. The excipient facilitates the compatibility of the 10 medicament with the propellant and also lowers the discharge pressure to an acceptable range, i.e., about  $2.76-5.52 \times 10^5$  newton/meter<sup>2</sup> absolute (40 to 80 psi), preferably  $3.45-4.83 \times 10^5$  newton/meter<sup>2</sup> absolute (50 to 70 psi). The excipient chosen must be non-reactive with the medicaments, relatively non-toxic, and should have a vapor pressure below about  $3.45 \times 10^5$  newton/meter<sup>2</sup> absolute (50 15 psi).

As used hereinafter the term "medium chain fatty acids" refers to chains of alkyl groups terminating in a -COOH group and having 6-12 carbon atoms, preferably 8-10 carbon atoms. The term "short chain fatty acids" refers to chains of alkyl groups terminating in a --COOH group and having 4-8 carbon atoms. The 20 term "alcohol" includes C<sub>1</sub>-C<sub>3</sub> alcohols, such as methanol, ethanol and isopropanol.

Among the preferred excipients are: propylene glycol diesters of medium chain fatty acids available under the tradename Miglyol 840 (from Huls America, Inc. Piscataway, N.J.); triglyceride esters of medium chain fatty acids available under the tradename Miglyol 812 (from Huls); perfluorodimethylcyclobutane

available under the tradename Vertrel 245 (from E. I. DuPont de Nemours and Co. Inc. Wilmington, Del.); perfluorocyclobutane available under the tradename octafluorocyclobutane (from PCR Gainsville, Fla.); polyethylene glycol available under the tradename EG 400 (from BASF Parsippany, N.J.); menthol (from Pluess-  
5 Stauffer International Stanford, Conn.); propylene glycol monolaurate available under the tradename lauroglycol (from Gattefosse Elmsford, N.Y.); diethylene glycol monoethylether available under the tradename Transcutol (from Gattefosse); polyglycolized glyceride of medium chain fatty acids available under the tradename Labrafac Hydro WL 1219 (from Gattefosse); alcohols, such as ethanol, methanol  
10 and isopropanol; eucalyptus oil available (from Pluses-Stauffer International); and mixtures thereof.

A surfactant is frequently included in aerosol formulations, for purposes such as assisting with maintaining a stable suspension of the drug and lubricating the metering valve. The formulation of the present invention does not require a  
15 surfactant for maintenance of ready dispersability (such as by moderate agitation immediately prior to use), as the drugs form loose floccules in the propellant and does not exhibit a tendency to settle or compact. In the case of HFA 227 upon undisturbed storage, the drug particles remain suspended in their flocculated state. Thus, a surfactant optionally may be added to lower the surface and interfacial  
20 tension between the medicaments and the propellant. Where the medicaments, propellant and excipient are to form a suspension, a surfactant may or may not be required. Where the medicament, propellant and excipient are to form a solution, a surfactant may or may not be necessary, depending in part, on the solubility of the particular medicament and excipient. The surfactant may be any suitable, non-toxic

compound which is non-reactive with the medicament and which substantially reduces the surface tension between the medicament, the excipient and the propellant and/or acts as a valve lubricant. Among the preferred surfactants are: oleic acid available under the tradename oleic acid NF6321 (from Henkel Corp.

5 Emery Group, Cincinnati, Ohio); cetylpyridinium chloride (from Arrow Chemical, Inc. Westwood, N.J.); soya lecithin available under the tradename Epikuron 200 (from Lucas Meyer Decatur, Ill.); polyoxyethylene(20) sorbitan monolaurate available under the tradename Tween 20 (from ICI Specialty Chemicals, Wilmington, Del.); polyoxyethylene(20) sorbitan monostearate available under the tradename Tween 10 60 (from ICI); polyoxyethylene(20) sorbitan monooleate available under the tradename Tween 80 (from ICI); polyoxyethylene (10) stearyl ether available under the tradename Brij 76 (from ICI); polyoxyethylene (2) oleyl ether available under the tradename Brij 92 (frown ICI); Polyoxyethylene-polyoxypropylene-ethylenediamine block copolymer available under the tradename Tetronic 150 R1 (from BASF); 15 polyoxypropylene-polyoxyethylene block copolymers available under the tradenames Pluronic L-92, Pluronic L-121 end Pluronic F 68 (from BASF); castor oil ethoxylate available under the tradename Alkasurf CO-40 (from Rhone-Poulenc Mississauga Ontario,Canada); and mixtures thereof.

As with other drugs which have slight solubility in ethanol, there is a 20 tendency for mometasone furoate to exhibit crystal growth in ethanol-containing formulations. Formulation parameters which do not promote drug particle size growth are known. These parameters provide the advantage of minimizing the required ethanol concentrations, to reduce the potential for unpleasant taste

sensations and render the compositions more suitable for use by children and others with low alcohol tolerance.

A certain minimum level of ethanol is preferred to provide consistent and predictable delivery of the drug from a metered dose dispenser. This minimum level is about 1 weight percent of the total formulation, which results in a marginally acceptable drug delivery. Increased amounts of ethanol generally improve drug delivery characteristics. However, to prevent drug crystal growth in the formulation, it is preferred to limit the concentration of ethanol. Experimental data indicate that the ratio of the weight of mometasone furoate to the weight of ethanol is important in preventing particle size increases.

The active ingredients may be put into the containers housing the formulation as follows: the container that houses the medication can be filled with medicine, ethanol and a surfactant in single or multiple steps, preferably in a single step. Similarly, the propellant or mixture of propellants may be added to the container in the same or in multiple steps. The suspensions of the formulations of the present invention contain floccules of the ingredients. A floccule is an aggregation of particles that form a lattice type of structure that resists complete settling. The loose structure of the lattice permits the aggregates to break up easily and distribute readily with a small amount of agitation. More specifically, when mometasone is suspended in a propellant, over time the particles of mometasone will tend to flocculate in the center of the suspension. These particles readily disperse upon agitation or shaking of the metered dose inhaler canister. Surprisingly, the addition of formoterol to the suspension did not alter this phenomena. When the propellant is HFA 227, the formoterol fumarate and

mometasone furoate form floccules in suspension such that the mometasone and formoterol are aggregated with each other. When the propellant is HFA 134a, the presence of a bulking agent or carrier such as lactose in an amount of about 0.05% to about 0.3% by weight is preferred to enhance drug delivery upon actuation of the 5 inhaler. With 134a based formulations, the formoterol, mometasone and lactose have a tendency to sediment to the bottom of the canister because HFA 134a is less dense than HFA 227; thus shaking of the canister to re-form the suspension prior to actuation of the meter is preferred for uniform drug delivery. Other bulking agents that may be used in HFA 134a suspensions include, for example, mannitol, 10 glucose, sucrose and trehalose.

Formulations of the invention are made according to procedures customary in the art for other aerosol compositions. Typically, all components except the propellant are mixed and introduced into aerosol containers. The containers can then be chilled to temperatures below the boiling point of the propellant, and the 15 required amount of the chilled propellant added before the metering valve is crimped on to the container. Alternatively, the containers can be fitted with a metering valve before being filled with propellant, and the required quantity of propellant will be introduced through the valve.

The formulations of the present invention may be filled into the aerosol 20 containers using conventional filling equipment. Since HFA 227 and HFA 134a may not be compatible with all elastomeric compounds currently utilized in present aerosol valve assemblies, it may be necessary to substitute other materials, such as white buna rubber, or to utilize excipients and optionally surfactants which mitigate the adverse effects of HFA 227 or 134a on the valve components.

Suspensions of the present invention preferably may be prepared by either the pressure filling or cold filling procedures known in the art.

Depending on the particular application, the container may be charged with a predetermined quantity of formulation for single or multiple dosing. Typically, the container is sized for multiple-dosing, and, therefore it is very important that the formulation delivered is substantially uniform for each dosing. For example, where the formulation is for bronchodilation, the container typically is charged with a sufficient quantity of the formulation for 200 actuations.

Suitable suspensions may be screened in part by observing several physical properties of the formulation, i.e. the rate of particle agglomeration, the size of the agglomerates and the rate of particulate creaming/settling and comparing these to an acceptable standard. Such, suitable solutions may be screened/evaluated by measuring the solubility of the medicament over the entire recommended storage temperature range.

For metered dose inhalers, suspensions may be particularly preferred for efficacy and stability considerations. Those skilled in the art may choose to add one or more preservative, buffer, antioxidant, sweetener and/or flavors or other taste masking agents depending upon the characteristics of the formulation.

The available metering valve delivery volumes range from about 25 to about 100 microliters per actuation, while the amounts of drug substance required in a dose for treating a particular condition is generally about 10 to about 500 micrograms per valve actuation. These two factors combined pose limitations that dictate the points within the foregoing ethanol parameters for a given formulation. The determination of such amounts is within the skill of workers in this art.

In formulations of the present invention which are suitable for treating lower respiratory system disorders such as asthma, at least a substantial portion of the drug is present as suspended particles having respirable sizes, e.g., about 0.5 to about 10 micrometers in their largest dimension. In formulations which are suitable for treating upper respiratory system disorders such as rhinitis, somewhat larger drug particles may be permissible, but the foregoing size range remains preferred.

Where the active compound forms a suspension, the particle size should be relatively uniform, with substantially all the particles preferably ranging between about 0.1-25 microns, preferably 0.5-10 microns, more preferably 1-5 microns.

Particles larger than 25 microns may be held up in the oropharyngeal cavity, while particles smaller than about 0.5 micron preferably are not utilized, since they would be more likely to be exhaled and, therefore, not reach the lungs of the patient.

Also within the scope of the present invention is methods of treating diseases of the airways susceptible to treatment with mometasone furoate and formoterol fumarate in effective amounts as set forth in examples 3, 4 and 5 below. The medicaments may be administered once or twice a day in accordance with the doses set forth in examples 3, 4 and 5.

Another aspect of the present invention comprises novel formulations comprising a dispersion system of a well mixed ternary blend of the two drug substance powders mometasone furoate and formoterol fumarate dispersed with a third powder-surfactant, such as, for example lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate, magnesium laurate and other suitable dry powder blend surfactants as are known to one of skill in the art.

The dry blend may be mixed for example in a Turbula Mixer T2C for about 5 minutes, or for such amount of time is known to one of skill in the art to achieve a uniform blend of the powders. This dispersion system is metered individually into each inhaler can with a powder filling instrument, such as for example by an

5 Autodose Powdermiser - One Too Many System, into 15 mL aluminum teflon coated (FPT - fluorinated ethylene copolymer) or other polymer coated, cans. The cans can then be crimped with 63 microliter valves or the like and filled with HFA-227 or HFA-134a propellant using propellant filling equipment, such as, for example, a Pamasol Model P2008/012. The cans filled with the suspension product are

10 thereafter sonicated by a sonicator, such as, for example, a Branson 5210 sonicator for about 5 minutes as is known to one in the art.

These particular formulations allow for the manufacture of a two drug substance combination MDI that exhibits a consistent Drug Content Uniformity (DCU) without the use of additional excipients and/or additives. The use of this

15 type of dry 2-step filling procedure precludes the possibility of crystal growth of the active ingredients during the filling process and assures a consistent particle size distribution in the product filled during the beginning, middle and end of the filling process. This formulation and filling process assure adequate dispersion of the particles in the suspending medium HFA-227, absence of crystal growth, absence

20 of caking and adequate drug content uniformity upon delivery of the dose.

Certain aspects of the invention are further described in the following examples. In the examples, "percent" indicates weight percentage unless the context clearly indicates otherwise. The examples below further describe the present invention.

The following dry powder blend samples were prepared.

Example 1

**Table 1. Dry Powder Blends of Mometasone Furoate (91%), Formoterol Fumarate (9%) & Lecithin (0.1%, 0.01% and 0.02%)\***

Mometasone Furoate (mg)	Formoterol Fumarate (mg)	Lecithin (mg)	Total Weight of Blend (mg)	Weight Per Can (mg)
616.0	61.70	0.686	678.4	13.57
621.0	62.00	0.070	683.1	13.66
621.0	61.80	0.144	682.9	13.66

\*: All weights presented on the w/w basis in the ternary blend.

5

As is apparent, the weigh ratio of mometasone furoate to formoterol fumarate is roughly about 10 to 1. To prepare, directly mix a dry powder blend of the mometasone furoate, formoterol fumarate and lecithin in a Turbula mixer for about 5 minutes in the above identified amounts. Thereafter, meter the mixture into 10 the 15 mL canister using an Autodose Powdernium powder filling instrument or the like. Thereafter, crimp with a 63 microliter valve and add the propellant up to about 10 g/can. Then, sonicate for 5 minutes.

Example 2

**Table 2. MDI Formulation Blends of Mometasone Furoate, Formoterol Fumarate, Lecithin and HFA-227\***

Mometasone Furoate (%)	Formoterol Fumarate (%)	Lecithin (%)	HFA-227 (%)
0.1	0.01	0.01	99.88
0.1	0.01	0.001	99.89
0.1	0.01	0.002	99.89

\*: All weights presented on the w/w basis in the finished product.

15

Table 2 describes the various amounts of the active ingredients and surfactant when combined with HFA-227 in the finished metered dose inhaler canister.

Certain other aspects of the invention are further described in the following examples. Again, in the examples, "percent" indicates weight percentage unless the context clearly indicates otherwise. The examples below further describe the present invention.

Examples 3, 4 and 5 provide examples of the varying amounts of various ingredients of the formulations of the present invention.

Example 3

Formulation Prototype (Drug:Drug) Ratio	Mometasone Furoate (%)	Formoterol Fumarate (%)	Oleic Acid (%)	Ethanol (%)	HFA-227 (%)
A (100 µg:8 µg)	0.112	0.009	0.001	2.378	97.5
B (50 µg:6 µg)	0.056	0.007	0	2.437	97.5
C (100 µg:8 µg)	0.112	0.009	0.011	2.368	97.5
D (200 µg:12 µg)	0.224	0.014	0.011	2.251	97.5
E (100 µg:8 µg)	0.112	0.009	0	2.379	97.5
F (50 µg:6 µg)	0.056	0.007	0.001	2.436	97.5
G (50 µg:6 µg)	0.056	0.007	0.011	2.426	97.5
H (50 µg:6 µg)	0.056	0.007	0.011	1.5	98.426
I (50 µg:6 µg)	0.056	0.007	0.011	1.75	98.176
J (50 µg:6 µg)	0.056	0.007	0.0	1.5	98.437
K (50 µg:6 µg)	0.056	0.007	0.0	1.75	98.187
L (200 µg:12 µg)	0.224	0.014	0.011	1.5	98.251
M (200 µg:12 µg)	0.224	0.014	0.011	1.75	98.001
N (200 µg:12 µg)	0.224	0.014	0.0	1.5	98.262
O (200 µg:12 µg)	0.224	0.014	0.0	1.75	98.012

Example 4

Formulation Prototype (Drug:Drug)	Mometasone Furoate (%)	Formoterol Fumarate (%)	Oleic Acid (%)	Ethanol (%)	HFA-134a (%)
Ratio					
A (100 µg:8 µg)	0.112	0.009	0.001	2.378	97.5
B (50 µg:6 µg)	0.056	0.007	0	2.437	97.5
C (100 µg:8 µg)	0.112	0.009	0.011	2.368	97.5
D (200 µg:12 µg)	0.224	0.014	0.011	2.251	97.5
E (100 µg:8 µg)	0.112	0.009	0	2.379	97.5
F (50 µg:6 µg)	0.056	0.007	0.001	2.436	97.5
G (50 µg:6 µg)	0.056	0.007	0.011	2.426	97.5
H (50 µg:6 µg)	0.056	0.007	0.011	1.5	98.426
I (50 µg:6 µg)	0.056	0.007	0.011	1.75	98.176
J (50 µg:6 µg)	0.056	0.007	0.0	1.5	98.437
K (50 µg:6 µg)	0.056	0.007	0.0	1.75	98.187
L (200 µg:12 µg)	0.224	0.014	0.011	1.5	98.251
MP (200 µg:12 µg)	0.224	0.014	0.011	1.75	98.001
N (200 µg:12 µg)	0.224	0.014	0.0	1.5	98.262
O (200 µg:12 µg)	0.224	0.014	0.0	1.75	98.012

Example 5

Formulation Prototype (Drug:Drug) Ratio	Mometasone Furoate (%)	Formoterol Fumarate (%)	Oleic Acid (%)	Ethanol (%)	HFA-227/HFA- 134a (50:50) (%)
A (100 µg:8 µg)	0.112	0.009	0.001	2.378	97.5
B (50 µg:6 µg)	0.056	0.007	0	2.437	97.5
C (100 µg:8 µg)	0.112	0.009	0.011	2.368	97.5
D (200 µg:12 µg)	0.224	0.014	0.011	2.251	97.5
E (100 µg:8 µg)	0.112	0.009	0	2.379	97.5
F (50 µg:6 µg)	0.056	0.007	0.001	2.436	97.5
G (50 µg:6 µg)	0.056	0.007	0.011	2.426	97.5
H (50 µg:6 µg)	0.056	0.007	0.011	1.5	98.426
I (50 µg:6 µg)	0.056	0.007	0.011	1.75	98.176
J (50 µg:6 µg)	0.056	0.007	0.0	1.5	98.437
K (50 µg:6 µg)	0.056	0.007	0.0	1.75	98.187
L (200 µg:12 µg)	0.224	0.014	0.011	1.5	98.251
M (200 µg:12 µg)	0.224	0.014	0.011	1.75	98.001
N (200 µg:12 µg)	0.224	0.014	0.0	1.5	98.262
O (200 µg:12 µg)	0.224	0.014	0.0	1.75	98.012

The formulations of the present invention were further analyzed using an Andersen Cascade Impactor as described in Examples 6 and 7. The Andersen Cascade Impactor is widely used for measuring the particle size distribution of airborne particles and more specifically pharmaceutical aerosols. The eight stage 5 Andersen Impactor separates the sample into nine size intervals when used with a backup filter after the last impaction stage. In Figures 1 to 4, this corresponds Stage 0 of particles having a particle size less than 10  $\mu\text{m}$  to a particle size of 0.65-0.43  $\mu\text{m}$  in stage 8, with the final stage corresponding to the filter for particles less than 0.43  $\mu\text{m}$ . The measurement of the particle size at the "throat" in the figures 10 corresponds to the entry port of the Impactor. The fine particle fraction is defined as the percentage of particles having a particle size of less than 4.7  $\mu\text{m}$ . The fine particle dose is defined as the amount in  $\mu\text{g}$  per dose that is less than 4.7  $\mu\text{m}$  in size in each actuation. The  $\mu\text{g}/\text{shot}$  is the total amount of emitted drug product that 15 exits the metered dose inhaler upon actuation. The determination of the particle size distribution of the emitted dose of the formulation using an Andersen Cascade Impactor is known to one of skill in the art.

#### Example 6

20 Andersen Cascade Impactor data on Formoterol/Mometasone 6/50  $\mu\text{g}/\text{actuation}$  combination Inhaler – HFA 227, without bulking agent system

	Mometasone Furoate				
	Initial	1 Month	3 Month	4 Month	
Fine Particle Fraction %	36.5	16.4	25.3	9.8	30.4
Fine Particle Dose ( $\mu\text{g}/\text{shot}$ )	19.7	9.2	13.9	5.3	16.1
MMAD (microns)	3.7	5.0	4.1	6.3	4.2
$\mu\text{g}/\text{shot}$ (metered dose)	62.9	62.6	62.4	60.5	61.5
					63.3

Formoterol Fumarate						
	Initial	1 Month		3 Month		4 Month
		4C/40C	40C/75%	4C/40C	25C/60%	40C/75%
Fine Particle Fraction %	46.3	39.0	41.1	35.2	47.3	40.1
Fine Particle Dose (µg/shot)	2.6	2.2	2.4	1.9	2.6	2.2
MMAD (microns)	3.2	3.3	3.2	3.3	3.2	3.4
µg /shot (metered dose)	6.6	6.3	6.6	6.3	6.5	6.5

A formulation containing 6 µg of formoterol fumarate and 50 µg of mometasone furoate using HFA 227 in the absence of a bulking agent or carrier in a metered dose inhaler was analyzed by an Andersen Cascade Impactor to analyze the amount of active drug ingredients and the particle size of the actives exiting the inhaler over time. As can be seen, the fine particle dose of the mometasone and formoterol over time and through temperature cycling under the conditions specified was maintained within acceptable limits (19.7 to 10.4 for mometasone and 2.6 to 2.2 for formoterol at the 4 month point). The metered dose for both actives over time was also within acceptable limits (62.9 to 63.3 for mometasone and 6.6 to 6.5 for formoterol at the 4 month point). This data corresponds to the particle size distribution for mometasone and formoterol set forth in figures 1 and 2, respectively. This data indicates improved and acceptable drug delivery of the two actives.

While the fine particle fraction of mometasone furoate appeared to decrease by nearly half, this was attributed to the coarseness of the grade of mometasone furoate used. There is a rank order correlation of the quality of the product with a decrease in the size range of the corresponding drug substance suspended in the product. It was determined that drug substance containing a high proportion of large crystals that are greater than 5 to 10 microns produces a product with an aerodynamic particle size distribution that is outside the range of a typical

efficacious topical lung medication. The product containing coarser drug product also shows unacceptable particle growth with time and temperature.

A finer particle size distribution of the mometasone furoate improves the fine particle fraction of the formulation exiting the inhaler upon actuation of the metered dose inhaler. Indeed, the grade of mometasone used in the above example had a 5 percent change in fine particle size of about 50% after two weeks of temperature cycling at -10 °C and 40 °C. However, with a similar mdi using mometasone furoate alone, but with a finer grade of mometasone furoate, it showed only about a 10 15% or less change in fine particle size under the same cycling conditions. This results in an increase in the fine particle fraction with regards to the mometasone, and thus improved drug delivery of the mometasone. Thus, it has been found that 15 when a finer particle size grade of the drug substance is used, a product is produced which has suspended drug particles which do not exhibit particle growth with time and temperature. The aerodynamic particle size distribution is well within the range of a typical efficacious topical lung medication, e.g., greater than 50% of the particles are less than 4.7 microns. It also shows no significant particle growth with time and temperature.

In the case of the oral MDI containing mometasone furoate, an example of 20 an acceptable product profile for the 100 µg /actuation strength, using an Andersen Cascade Impactor and 1-liter entry port, is given below. It should be noted that the data is based on two actuations of the metered dose inhaler.

Table 1

ANDERSEN CASCADE IMPACTOR STAGE	AMOUNT OF PARTICLE DEPOSITED ON PLATES
Group 1- Entry port + Stage 0	8-22 $\mu$ g
Group 2 - Stage 1 + Stage 2	12-21 $\mu$ g
Group 3 - Stage 3 + Stage 4	122-140 $\mu$ g
Group 4 - Stage 5-Filter	22-41 $\mu$ g

The percentage of fine particles in group 1 ranges from about 4.9% to about 9.8%. The percentage of fine particles in group 2 ranges from about 7.3% to about 5 9.4%. The percentage of fine particles in stage 3 to the filter (groups 3 and4) should preferably be in a range of about 55% to about 85% where the fine particles have a particle size of less than about 4.7 $\mu$ m, preferably 65% to 80%, or about 10 80%, or about 85%, and about 81% to about 89% based upon data from above table. Finally, the percentage of fine particles in group 4 ranges from about 13.4% to about 18.3%.

The size of the suspended mometasone furoate drug contained in the drug product may be controlled in various ways. The drug substance may be more 15 efficiently milled prior to product batch manufacture. This could include reducing the micronization feed rate, employing centrifugal classification to remove larger particles and increasing the number of cycles the material is fed into the micronizer e.g., double micronizing. Alternatively, the drug substance may be spray dried prior to product batch manufacture, for example, by super critical fluid technology, to create uniformly small drug substance particles. Further the method of

manufacture can be modified, e.g., by reducing the temperature of batch manufacture, reducing the level of alcohol used to prepare the drug concentrate, or reducing the homogenization time. Finally, other processes of controlling drug substance particle size that are known in the art, e.g., using surfactants or other particle size growth retardation approaches may also be used.

### Example 7

10 **Andersen Cascade Impactor data on Formoterol/Mometasone 6/50  
μg/actuation combination Inhaler – HFA 134a, low bulking agent system**

	Mometasone Furoate				
	Initial	1 Month		3 Month	4 Month
	-	4C/40C	40C/75%	4C/40C	25C/60%
Fine Particle Fraction %	25.7	20.1	20.1	20.0	22.6
Fine Particle Dose (μg/shct)	13.6	10.6	10.1	10.0	11.4
MMAD (microns)	3.9	4.3	4.3	4.6	4.3
μg /shot (metered dose)	64.1	65.0	62.2	62.6	62.1
					63.7

	Formoterol Fumarate				
	Initial	1 Month		3 Month	4 Month
	-	4C/40C	40C/75%	4C/40C	25C/60%
Fine Particle Fraction %	42.5	38.0	41.3	40.2	43.6
Fine Particle Dose (μg/shot)	2.4	2.0	2.1	2.2	2.3
MMAD (microns)	2.9	3.1	2.9	3.2	3.0
/shot (metered dose)	6.9	6.5	6.3	6.8	6.7
					6.6

15 A formulation containing 6 μg of formoterol fumarate and 50 μg of mometasone furoate using HFA 134a with lactose as a bulking agent in a metered dose inhaler was analyzed by an Andersen Cascade Impactor to analyze the amount of active drug ingredients and the particle size of the actives exiting the inhaler over time. As can be seen, the fine particle dose of the mometasone and formoterol over time and through temperature cycling was maintained within acceptable limits (13.6 to 8.8 for mometasone and 2.4 to 2.1 for formoterol). Additionally, the metered dose actually delivered was also maintained over time

within acceptable limits (64.1 to 63.7 for mometasone, 6.9 to 6.6 for formoterol).

These data correspond to the particle size distribution for formoterol and mometasone set forth in figures 3 and 4, respectively. The fine particle fraction for both mometasone and formoterol was maintained within acceptable limits. These

5 data also indicate improved drug delivery of the two actives via metered dose inhalation. Additionally, as set forth in example 6, with a similar mdi using mometasone furoate alone, but with a finer grade of mometasone furoate showed only about a 15% or less change in fine particle size under the same cycling conditions. This results in an increase in the fine particle fraction with regards to

10 the mometasone, and thus improved drug delivery of the mometasone.

#### Example 8

The degradation products of the formulations of the present invention were analyzed at 4 months time at 40 °C and 75% relative humidity.

IMPURITY	HFA 277, NON-BULKED	HFA 134A, LOW BULKED
Formoterol deg. product - 2566	0.10	0.21
Total formoterol known deg. w/o SCH-2566	0.10	0.09
Total formoterol unknown degradation	0.13	0.38
Total formoterol degradation w/o XSCH-2566	0.23	0.47
Compound E	0.06	0.23
Total mometasone known deg. w/o Compound E	0	0
Total mometasone unknown degradation	0.13	0.13
Total mometasone degradation	0.19	0.35
Total related subs	0.51	1.03

As can be seen, the non-bulked formulations containing the HFA 227 had substantially less degradation products as a whole as compared to the bulked formulations containing the HFA 134a. Specifically, the HFA 227 formulations contained less than 0.1% of a degradation product called compound E which is an epoxide type degradant associated with mometasone furoate. Formulations containing mometasone furoate containing less than 0.1% of compound E meet FDA specifications for the presence of this particular compound in inhalable formulations containing mometasone furoate.

### Example 9

10

#### **Drug Content Uniformity of Formoterol/Mometasone 6/50 µg/actuation combination Inhaler – HFA 227, no bulking agent system**

Mometasone Furoate		
	Initial	1 Month
	-	4C/40C
Overall Mean µg/shot	54.7	55.6
Relative Standard Deviation	11.5	9.6
		40C/75%
		54.9
		6.1

Formoterol Fumarate		
	Initial	1 Month
	-	4C/40C
Overall Mean µg/shot	5.7	5.5
Relative Standard Deviation	11.6	10.4
		40C/75%
		5.7
		6.6

15

### Example 10

20

#### **Drug Content Uniformity of Formoterol/Mometasone 6/50 µg/actuation combination Inhaler – HFA 134a, low bulking agent system**

Mometasone Furoate		
	Initial	1 Month
	-	4C/40C
Overall Mean µg/shot	59.1	55.7
Relative Standard Deviation	17.9	10.9
		40C/75%
		57.0
		19.6

Formoterol Fumarate		
	Initial	1 Month
	-	4C/40C
Overall Mean $\mu$ g/shot	6.2	5.6
Relative Standard Deviation	17.3	11.2
		40C/75%
		6.0
		26.1

The Drug Content Uniformity (DCU) of the inhaler was measured throughout the life of a 120 dose MDI to ascertain whether there was a consistency of dose of the active ingredients throughout the life of the product. Five canisters of each 5 formulation (HFA 227 or HFA 134a) were analyzed and each canister delivered 120 actuations of medication and the amount of actives exiting the inhaler per actuation was measured at varying actuations, e.g., numbers 11, 12, 13, 14, (beginning) 59, 60, 61, 62 (middle) and 117, 118, 119 and 120 (end). Means were determined for the beginning, middle and end actuations, and an overall mean was determined 10 and set forth in Examples 9 and 10 above. While the HFA 227 formulation had a lower relative standard deviation for the amount of drug emitted throughout the life of the MDI, both formulations yielded acceptable results for drug content uniformity over time.

The foregoing descriptions of various embodiments of the invention are 15 representative of various aspects of the invention, and are not intended to be exhaustive or limiting to the precise forms disclosed. Many modifications and variations undoubtedly will occur to those having skill in the art. It is intended that the scope of the invention shall be fully defined solely by the appended claims.

We Claim:

1. A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3-heptafluoropropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400 µg of mometasone furoate to about 12 µg of formoterol fumarate to about 50 µg of mometasone furoate to about 6 µg of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, and wherein the formulation is substantially free of a carrier.

10

2: The metered dose inhaler containing an aerosol suspension formulation for inhalation of claim 1 further comprising a surfactant.

15

3. The metered dose inhaler containing an aerosol suspension formulation for inhalation of claim 1, wherein the mometasone furoate is present in an amount of about 50 µg and the formoterol fumarate is present in an amount of about 6 µg.

20

4. The metered dose inhaler containing an aerosol suspension formulation for inhalation of claim 1, wherein the mometasone furoate is present in an amount of about 100 µg and the formoterol fumarate is present in an amount of about 6 µg.

5. The metered dose inhaler containing an aerosol suspension formulation for inhalation of claim 1, wherein the mometasone furoate is present in an amount of about 50 µg and the formoterol fumarate is present in an amount of about 8 µg.

6. The metered dose inhaler containing an aerosol suspension formulation for inhalation of claim 1, wherein the mometasone furoate is present in an amount of about 100  $\mu$ g and the formoterol fumarate is present in an amount of about 8  $\mu$ g.

5

7. The metered dose inhaler containing an aerosol suspension formulation for inhalation of claim 1, wherein the mometasone furoate is present in an amount of about 200  $\mu$ g and the formoterol fumarate is present in an amount of about 12  $\mu$ g.

10 8. The metered dose inhaler containing an aerosol suspension formulation for inhalation of claim 1, wherein the mometasone furoate is present in an amount of about 400  $\mu$ g and the formoterol fumarate is present in an amount of about 12  $\mu$ g.

9. A method for treating allergic and inflammatory reactions in the respiratory tract, comprising administering by inhalation an aerosol suspension formulation according to claim 1.

15 10. A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; a bulking agent present in an amount of about 0.05% to 0.3% by weight of the formulation; and 1,1,1,2-tetrafluoroethane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400  $\mu$ g of mometasone furoate to about 12  $\mu$ g of formoterol fumarate to about 50  $\mu$ g of mometasone furoate to about 6  $\mu$ g of

formoterol fumarate, and wherein the formoterol fumarate flocculates with the mometasone furoate.

11. The metered dose inhaler containing an aerosol suspension formulation for  
5 inhalation of claim 10 further comprising a surfactant.

12. The metered dose inhaler containing an aerosol suspension formulation for  
inhalation formulation of claim 10, wherein the mometasone furoate is present in an  
amount of about 50  $\mu$ g and the formoterol fumarate is present in an amount of  
10 about 6  $\mu$ g.

13. The metered dose inhaler containing an aerosol suspension formulation for  
inhalation formulation of claim 10, wherein the mometasone furoate is present in an  
amount of about 100  $\mu$ g and the formoterol fumarate is present in an amount of  
15 about 6  $\mu$ g.

14. The metered dose inhaler containing an aerosol suspension formulation for  
inhalation formulation of claim 10, wherein the mometasone furoate is present in an  
amount of about 50  $\mu$ g and the formoterol fumarate is present in an amount of  
20 about 8  $\mu$ g.

15. The metered dose inhaler containing an aerosol suspension formulation for  
inhalation formulation of claim 10, wherein the mometasone furoate is present in an

amount of about 100 µg and the formoterol fumarate is present in an amount of about 8 µg.

16. The metered dose inhaler containing an aerosol suspension formulation for  
5 inhalation formulation of claim 10, wherein the mometasone furoate is present in an amount of about 200 µg and the formoterol fumarate is present in an amount of about 12 µg.

17. The metered dose inhaler containing an aerosol suspension formulation for  
10 inhalation formulation of claim 10, wherein the mometasone furoate is present in an amount of about 400 µg and the formoterol fumarate is present in an amount of about 12 µg.

18. The metered dose inhaler containing an aerosol suspension formulation for  
15 inhalation formulation according to claim 10, wherein the bulking agent is selected from the group consisting of lactose, glucose, trehalose, sucrose and mannitol.

19. A method for treating allergic and inflammatory reactions in the respiratory tract, comprising administering by inhalation an aerosol suspension formulation  
20 according to claim 10.

20. A process for producing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising:

an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3,-heptaflouopropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400  $\mu$ g of mometasone furoate to about 12  $\mu$ g of formoterol fumarate to about 50  $\mu$ g of mometasone furoate to about 6  $\mu$ g of formoterol fumarate, wherein the formoterol fumarate is flocculated with the mometasone furoate in said aerosol suspension formulation, and wherein the formulation is free of a bulking agent, comprising the steps of:

- 5 a) mixing a dry powder blend of micronized mometasone furoate and formoterol fumarate with a dry powder surfactant to form a uniform mixture;
- 10 b) filling said mixture into a metered dose inhaler canister;
- c) crimping said canister with a metering valve; and
- d) filling said canister with a nonchlorofluorocarbon propellant.

21. The product produced by the process of claim 20.

15

22. The process according to claim 20, wherein the dry powder surfactant is selected from the group consisting of lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate, and magnesium laurate.

20

23. A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; a dry powder surfactant; and 1,1,1,2,3,3,3,-heptaflouopropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400  $\mu$ g of

mometasone furoate to about 12  $\mu\text{g}$  of formoterol fumarate to about 50  $\mu\text{g}$  of mometasone furoate to about 6  $\mu\text{g}$  of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, wherein the formulation is free of additional excipients, and wherein the metered dose inhaler emits a dose having

5 uniform drug content upon actuation of the metered dose inhaler.

24. A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3,-heptafluopropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400  $\mu\text{g}$  of mometasone furoate to about 12  $\mu\text{g}$  of formoterol fumarate to about 50  $\mu\text{g}$  of mometasone furoate to about 6  $\mu\text{g}$  of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, and wherein the formulation contains less than 0.1% of an epoxide degradation product of mometasone furoate.

15

25. A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate; an effective amount of formoterol fumarate; and 1,1,1,2,3,3,3,-heptafluopropane; wherein the ratio of mometasone furoate to formoterol fumarate is about 400  $\mu\text{g}$  of mometasone furoate to about 12  $\mu\text{g}$  of formoterol fumarate to about 50  $\mu\text{g}$  of mometasone furoate to about 6  $\mu\text{g}$  of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, wherein the percent of the fine particles dispensed upon

actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7 $\mu$ m.

26. The metered dose inhaler containing an aerosol suspension formulation for  
5 inhalation according to claim 25, wherein the percent of the fine particles dispensed  
upon actuation of the metered dose inhaler is about 65% to about 80%, and  
wherein said fine particles have a particle size of less than about 4.7 $\mu$ m.

1/4




FIG. 1

2/4




FIG. 2

3/4




FIG. 3

4/4




FIG. 4

**THIS PAGE BLANK (USPTO)**

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number  
WO 03/020253 A3(51) International Patent Classification: A61K 9/12,  
31/58, 31/167, A61P 11/06 // (A61K 31/58, 31/167)RO, RU, SE, SG, SI, SK, SI, LI, TM, IN, IR, IL, TZ, UA,  
US, UZ, VC, VN, YU, ZA, ZM

(21) International Application Number: PCT/US02/27336

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, FI,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PL, SE, SK,  
TR). OAPI patent (BE, BJ, CE, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG)

(22) International Filing Date: 27 August 2002 (27.08.2002)

(25) Filing Language: English

**Declarations under Rule 4.17:**

as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(a)) for the following designations: AT, BG, IL, IM, NL, PL, AZ, BY, BB, BG, RR, BY, BZ, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, TK, TR, LT, LU, MA, MD, MG, MK, MN, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, IN, IR, IT, TZ, UG, TZ, EC, FA, YU, ZA, ZM, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, FI, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PL, SE, SK, TR), OAPI patent (BE, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(b)) for all designations

(26) Publication Language: English

(30) Priority Data: 60/315,386 28 August 2001 (28.08.2001) US

**Published:**

with international search report

(71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US], Patent Department K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(72) Inventors: and

(75) Inventors/Applicants (for US only): SEQUEIRA, Joel, A. [US/US]; 6 Mary Ellen Drive, Edison, NJ 08820 (US). SHARPE, Stefan, A. [US/US]; 270 5th Street, Jersey City, NJ 07302 (US). HART, John, L. [GB/US]; 12 Cobble Lane, Bedminster, NJ 07921 (US).

(74) Agent: LIPKA, Robert, J.: Schering Plough Corporation, Patent Department-K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, TK, TR, IL, LU, IN, MA, MD, MG, MK, MN, MN, MZ, NO, NZ, PH, PL, PT

(88) Date of publication of the international search report: 22 May 2003

For two-letter codes and other abbreviations, refer to the "Guide to the Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A3

WO 03/020253 A3

(54) Title: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ASTHMA

(57) Abstract: Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and formoterol fumarate in fixed doses for inhaled delivery.

## INTERNATIONAL SEARCH REPORT

PCT/US 02/27336

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K9/12 A61K31/58 A61K31/167 A61P11/06 // (A61K31/58,  
 31:167)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
P, X	WO 01 78744 A (GLAXO GROUP LTD : ROCHE TREVOR CHARLES (GB); GAVIN BRIAN CHARLES (I) 25 October 2001 (2001-10-25) page 3, line 20 -page 4, line 26 page 6, line 23 - line 35 examples 1-3 ---	1-26
X	WO 00 51591 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); CLARKE JEREMY GUY) 8 September 2000 (2000-09-08) page 1, paragraph 2 - paragraph 3 page 3, paragraph 4 -page 6, paragraph 3 page 7, paragraph 4 -page 8, paragraph 1 example 1 --- -/-	1-26

 Further documents are listed in the continuation of box C Patent family members are listed in annex

## \* Special categories of cited documents

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*8\* document member of the same patent family

Date of the actual completion of the international search

21 February 2003

Date of mailing of the international search report

28/02/2003

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx 31 651 epo nl.  
Fax (+31-70) 340-3016

## Authorized officer

Giménez Miralles, J

## INTERNATIONAL SEARCH REPORT

PCT/US 02/27336

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate of the relevant passages	Relevant to claim N°
X	WO 00 53187 A (TROFAST JAN ;ASTRAZENECA AB (SE); BAUER CARL AXEL (SE)) 14 September 2000 (2000-09-14) page 3, line 10 - line 20 page 6, line 13 - line 20 examples 7,8 ---	1-26
Y	WO 98 08519 A (SCHERING CORP) 5 March 1998 (1998-03-05) page 4, line 24 -page 5, line 3 page 6, line 34 -page 7, line 31 examples ---	1-26
Y	WO 97 47286 A (JINKS PHILIP A ;OLIVER MARTIN J (GB); PALING SIMON G (GB); JAISWAL) 18 December 1997 (1997-12-18) page 4, line 12 -page 5, line 13 page 5, line 21 -page 6, line 16 examples ---	1-26
A	WO 00 44352 A (SCHERING CORP) 3 August 2000 (2000-08-03) claim 21 -----	1-26

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 02/27336

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/USA/ 210**

Continuation of Box I.1

Although claims 9 and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

## INTERNATIONAL SEARCH REPORT

PCT/US 02/27336

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0178744	A	25-10-2001	AU WO	4854101 A 0178744 A1		30-10-2001 25-10-2001
WO 0051591	A	08-09-2000	AU BR CA CN CZ WO EP HU JP NO NZ SK US	3284300 A 0008699 A 2362499 A1 1341017 T 20013168 A3 0051591 A1 1156790 A1 0200142 A2 2002538110 A 20013988 A 513742 A 12302001 A3 2002055494 A1		21-09-2000 26-12-2001 08-09-2000 20-03-2002 12-12-2001 08-09-2000 28-11-2001 29-06-2002 12-11-2002 16-08-2001 28-09-2001 03-12-2001 09-05-2002
WO 0053187	A	14-09-2000	AU WO	3687400 A 0053187 A1		28-09-2000 14-09-2000
WO 9808519	A	05-03-1998	AT AU AU BR CN CZ DE DE DK EP ES GR HK JP JP KR NO NZ PL PT SK TR TW WO ZA	202936 T 719079 B2 4232997 A 9711445 A 1233960 A 9900632 A3 69705628 D1 69705628 T2 927037 T3 0927037 A1 2159148 T3 3036674 T3 1018206 A1 3264496 B2 2000503673 T 2000035879 A 990956 A 334112 A 331828 A1 927037 T 25399 A3 9900379 T2 475901 B 9808519 A1 9707668 A		15-07-2001 04-05-2000 19-03-1998 24-08-1999 03-11-1999 14-07-1999 16-08-2001 08-05-2002 24-09-2001 07-07-1999 16-09-2001 31-12-2001 12-10-2001 11-03-2002 28-03-2000 26-06-2000 28-04-1999 28-07-2000 02-08-1999 31-10-2001 10-12-1999 21-05-1999 11-02-2002 05-03-1998 26-02-1998
WO 9747286	A	18-12-1997	AU AU CA EP JP NO NZ US WO ZA	726382 B2 3373997 A 2257841 A1 0934057 A1 2000513340 T 985720 A 333202 A 6054488 A 9747286 A1 9704546 A		02-11-2000 07-01-1998 18-12-1997 11-08-1999 10-10-2000 11-02-1999 23-06-2000 25-04-2000 18-12-1997 23-11-1998
WO 0044352	A	03-08-2000	AU	3470000 A		18-08-2000

## INTERNATIONAL SEARCH REPORT

PCT/US 02/27336

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0044352 A		CA 2360649 A1 CN 1341013 T EP 1146859 A1 JP 2002535352 T WO 0044352 A1	03-08-2000 20-03-2002 24-10-2001 22-10-2002 03-08-2000

**THIS PAGE BLANK (USPTO)**